[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100272246":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":46,"responsibleParty":76,"collaborators":78,"id":82,"slug":40,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":40,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":40,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":49,"whyStopped":40,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"The University of Texas Health Science Center at San Antonio","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Exendin-(9-39)","EXPERIMENTAL","To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.",[13],"Drug: Exendin-(9-39)",{"label":15,"type":10,"description":16,"interventionNames":17},"Atropine","to evaluate the effect of neural activation on insulin secretion and glucose metabolism",[18],"Drug: Atropine",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.",[9],[25],"no other name for Exendin-(9-39)",{"type":21,"name":15,"description":27,"armGroupLabels":28,"otherNames":29},"A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.",[15],[30],"Atropine sulfate",[32],{"name":33,"affiliation":5,"role":34},"Marzieh Salehi, MD, MS","PRINCIPAL_INVESTIGATOR",[36,42],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Marzieh Salehi, MD MS","CONTACT","210-567-6691",null,"salehi@uthscsa.edu",{"name":43,"role":38,"phone":44,"phoneExt":40,"email":45},"Jennifer Foster, MSN","210-450-8696","fosterj6@uthscsa.edu",[47,66],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Texas Diabetes Institute - University Health System","RECRUITING","San Antonio","Texas","78207","United States",{"type":55,"coordinates":56},"Point",[57,58],-98.49363,29.42412,{"lat":58,"lon":57},[61,64,65],{"name":62,"role":38,"phone":39,"phoneExt":40,"email":63},"Marzieh Salehi, MD","hansisdiarte@uthscsa.edu",{"name":43,"role":38,"phone":44,"phoneExt":40,"email":45},{"name":62,"role":34,"phone":40,"phoneExt":40,"email":40},{"facility":67,"status":49,"city":50,"state":51,"zip":68,"country":53,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"South Texas Veterans Health Care System","78229",{"type":55,"coordinates":70},[57,58],{"lat":58,"lon":57},[73,74,75],{"name":62,"role":38,"phone":39,"phoneExt":40,"email":41},{"name":43,"role":38,"phone":44,"phoneExt":40,"email":45},{"name":62,"role":34,"phone":40,"phoneExt":40,"email":40},{"type":77,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR",[79],{"name":80,"class":81},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100272246",false,"NCT02823665","The Effects of Bariatric Surgeries on Glucose Metabolism","Inclusion Criteria:\n\n* Hypoglycemic RYGB patients with documented blood glucose level \\\u003C50 mg\u002Fdl\n* Asymptomatic individuals with bariatric surgery\n* Healthy non-surgical patients with no personal history of diabetes\n* Subjects must physically be able to come to our clinical research center Cedars-Sinai Medical Center\n\nExclusion Criteria:\n\n* Active heart, lung, liver, gastrointestinal or kidney disease; unable to give informed consent; pregnancy; uncontrolled high blood pressure or high cholesterol; significant anemia (hemoglobin \\\u003C11g\u002FdL); prisoners or institutionalized individuals; type 2 diabetes mellitis; development of any serious medical or psychiatric illness during recruitment or studies;\n* RYGB patients will be disqualified if they have gastric outlet obstruction or severe diarrhea.\n* Healthy non-surgical patients with personal history of diabetes\n\nFor administration of atropine, the following exclusions also apply:\n\n* History of glaucoma\n* Uncontrolled hypertension (any subjects with BP\\>140\u002F90 and history of dyslipidemia\n* Taking any medication that might interact with atropine and cannot be stopped will be excluded from the study)\n* Myasthenia gravis\n* Brain pathology\n* Enlarged prostate in men",true,"ALL","18 Years","65 Years",{"count":92,"type":93},200,"ESTIMATED","INTERVENTIONAL",[96],"EARLY_PHASE1","The purpose of this study is learn the effect of gastric bypass surgery and sleeve gastrectomy on glucose metabolism mediated by neural and hormonal factors initiated after eating.",[99,100,101,102],"Post Bariatric Surgery","Gastric Bypass","Sleeve Gastrectomy","Hypoglycemia After Gastric Bypass",[104,105,106,107],"gastric bypass surgery","Hypoglycemia","sleeve gastrectomy","glucose tolerance","2025-09-08",{"date":110,"type":111},"2025-09-09","ACTUAL",{"date":113,"type":40},"2015-07",{"date":115,"type":93},"2027-08",{"name":5,"class":6},2]